Crinetics Pharmaceuticals, Inc.(CRNX) Stock Research - Grey Stern Research

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis

$57.69 (1.02%)

CRNX Financial Performance


Use the table below to view Crinetics Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $57.69 -
52 Week Low $32.56 -
52 Week High $62.53 -
Market Cap $5.4 Billion 2/16
Gross Margin 0% 9/16
Profit Margin 0% 1/16
EBITDA margin -100% 1/16
Q3 - 2024 Revenue $0 9/16
Q3 - 2024 Earnings -$76.8 Million 14/16
Q3 - 2024 Free Cash Flow -$63.4 Million 13/16
Trailing 4 Quarters Revenue $1.0 Million 8/16
Trailing 4 Quarters Earnings -$277.9 Million 15/16
Quarterly Earnings Growth -34% 13/16
Annual Earnings Growth -32% 13/16
Quarterly Revenue Growth -100% 14/16
Annual Revenue Growth -69% 15/16
Cash On Hand $317.3 Million 2/16
Short Term Debt $7.4 Million 4/16
Long Term Debt $45.1 Million 4/16

Crinetics Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Crinetics Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/16
PS 5149.21 1/16
PB 6.42 2/16
PC 16.86 3/16
Liabilities to Equity 0.13 12/16
ROA -0.30 3/16
ROE -0.33 3/16
Current Ratio 8.98 4/16
Quick Ratio 8.26 4/16
Long Term Debt to Equity 0.05 8/16
Debt to Equity 0.06 9/16
Burn Rate 3.94 6/16
Cash to Cap 0.06 14/16
CCR 0.82 8/16
EV to EBITDA -57.92 15/16
EV to Revenue 4894.42 1/16

Company Details

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CEO: Dr. R. Scott Struthers

Website: https://www.crinetics.com

Address: 10222 Barnes Canyon Rd Bldg 2 San Diego, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Crinetics Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Crinetics Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Cytokinetics, Incorporated CYTK $5.9 Billion
REGENXBIO Inc. RGNX $433.0 Million
Merus N.V. MRUS $3.0 Billion
Alector, Inc. ALEC $215.5 Million
Harpoon Therapeutics, Inc. HARP $865.1 Million
Kezar Life Sciences, Inc. KZR $50.7 Million
TCR2 Therapeutics Inc. TCRR $58.1 Million
Black Diamond Therapeutics, Inc. BDTX $133.0 Million
Passage Bio, Inc. PASG $43.9 Million
Kronos Bio, Inc. KRON $61.5 Million
Inhibrx, Inc. INBX $218.6 Million
Viridian Therapeutics, Inc. VRDN $1.6 Billion
Lyell Immunopharma, Inc. LYEL $268.8 Million
Icosavax, Inc. ICVX $769.0 Million
LianBio LIAN $34.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CRNX Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 0 -$76.8 Million
Q2 2024 $ 399,000 -$74.1 Million
Q1 2024 $ 640,000 -$66.9 Million
Q4 2023 $ 0 -$60.1 Million
Q3 2023 $ 346,000 -$57.5 Million
Q2 2023 $ 988,000 -$51.0 Million
Q1 2023 $ 2.7 Million -$44.0 Million
Q4 2022 $ 709,000 -$42.4 Million

View All

CRNX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $317.3 Million $937.4 Million $52.5 Million $833.0 Million
Q2 2024 $302.2 Million $935.5 Million $53.3 Million $830.8 Million
Q1 2024 $395.9 Million $978.2 Million $52.5 Million $874.9 Million
Q4 2023 $54.9 Million $635.4 Million $51.7 Million $539.1 Million
Q3 2023 $142.8 Million $641.5 Million $52.2 Million -$593.6 Million
Q2 2023 $39.6 Million $293.3 Million $2.6 Million $254.1 Million
Q1 2023 $41.2 Million $314.0 Million $2.8 Million -$485.2 Million
Q4 2022 $32.7 Million $352.2 Million $2.0 Million -$439.2 Million

View All

CRNX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$63.4 Million -$528,000 $16.4 Million
Q2 2024 -$46.6 Million -$955,000 -$93.8 Million
Q1 2024 -$54.2 Million -$1.3 Million $341.0 Million
Q4 2023 -$39.5 Million -$935,000 -$87.9 Million
Q3 2023 $0 $0 $0
Q2 2023 -$46.0 Million -$237,000 -$1.6 Million
Q1 2023 -$40.7 Million -$16,000 $8.5 Million
Q4 2022 -$35.5 Million -$274,000 $1.8 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions